A Durham startup focused on developing therapeutics to treat "undruggable" cancer targets says it has raised $15.9 million.
The company, Ten63 Therapeutics, announced Tuesday it has closed an oversubscribed Series A round that will support the startup as it builds out its internal pipeline of potential therapeutics and expands its computational drug discovery platform.
Durham's Hatteras Venture Partners led the round, which included participation from Morpheus Ventures, SOSV, Draper Associates,…
